SEER. Cancer stat facts: myeloma. Accessed October 25, 2024. Available at: https://seer.cancer.gov/statfacts/html/mulmy.html

• PubMed
SEER. Cancer stat facts: myeloma. Accessed October 25, 2024. Available at: https://seer.cancer.gov/statfacts/html/mulmy.html)| false
• Search Google Scholar
• Export Citation

Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17–48.

• PubMed
Siegel RL, Miller KD, Wagle NS, Cancer statistics, 2023. CA Cancer J Clin 2023;73:17–48.)| false
• Search Google Scholar
• Export Citation

Chari A, Martinez-Lopez J, Mateos MV, et al. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood 2019;134:421–431.

• PubMed
Chari A, Martinez-Lopez J, Mateos MV, Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood 2019;134:421–431.)| false
• Search Google Scholar
• Export Citation

Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 2020;396:186–197.

• PubMed
Dimopoulos M, Quach H, Mateos MV, Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 2020;396:186–197.)| false
• Search Google Scholar
• Export Citation

Usmani SZ, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol 2022;23:65–76.

• PubMed
Usmani SZ, Quach H, Mateos MV, Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol 2022;23:65–76.)| false
• Search Google Scholar
• Export Citation

Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 2021;397:2361–2371.

• PubMed
Moreau P, Dimopoulos MA, Mikhael J, Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 2021;397:2361–2371.)| false
• Search Google Scholar
• Export Citation

Sonneveld P, Zweegman S, Cavo M, et al. Carfilzomib, pomalidomide, and dexamethasone as second-line therapy for lenalidomide-refractory multiple myeloma. HemaSphere 2022;6:e786.

• PubMed
Sonneveld P, Zweegman S, Cavo M, Carfilzomib, pomalidomide, and dexamethasone as second-line therapy for lenalidomide-refractory multiple myeloma. HemaSphere 2022;6:e786.)| false
• Search Google Scholar
• Export Citation

Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 2017;130:974–981.

• PubMed
Chari A, Suvannasankha A, Fay JW, Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 2017;130:974–981.)| false
• Search Google Scholar
• Export Citation

Dimopoulos MA, Terpos E, Boccadoro M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22:801–812.

• PubMed
Dimopoulos MA, Terpos E, Boccadoro M, Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22:801–812.)| false
• Search Google Scholar
• Export Citation

Siegel DS, Schiller GJ, Samaras C, et al. Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. Leukemia 2020;34:3286–3297.

• PubMed
Siegel DS, Schiller GJ, Samaras C, Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. Leukemia 2020;34:3286–3297.)| false
• Search Google Scholar
• Export Citation

Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 2019;394:2096–2107.

• PubMed
Attal M, Richardson PG, Rajkumar SV, Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 2019;394:2096–2107.)| false
• Search Google Scholar
• Export Citation

Dimopoulos MA, Leleu X, Moreau P, et al. Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia 2021;35:562–572.

• PubMed
Dimopoulos MA, Leleu X, Moreau P, Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia 2021;35:562–572.)| false
• Search Google Scholar
• Export Citation

Voorhees PM, Suman VJ, Tuchman SA, et al. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol 2021;96:1595–1603.

• PubMed
Voorhees PM, Suman VJ, Tuchman SA, A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol 2021;96:1595–1603.)| false
• Search Google Scholar
• Export Citation

Krishnan AY, Kapoor P, Palmer J, et al. A phase I/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R/R) multiple myeloma: initial results. J Clin Oncol 2016;34 (Suppl):Abstract 8008.

• PubMed
Krishnan AY, Kapoor P, Palmer J, A phase I/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R/R) multiple myeloma: initial results. J Clin Oncol 2016;34 (Suppl):Abstract 8008.)| false
• Search Google Scholar
• Export Citation

Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:1319–1331.

• PubMed
Dimopoulos MA, Oriol A, Nahi H, Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:1319–1331.)| false
• Search Google Scholar
• Export Citation

Bahlis NJ, Dimopoulos MA, White DJ, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 2020;34:1875–1884.

• PubMed
Bahlis NJ, Dimopoulos MA, White DJ, Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 2020;34:1875–1884.)| false
• Search Google Scholar
• Export Citation

Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372:142–152.

• PubMed
Stewart AK, Rajkumar SV, Dimopoulos MA, Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372:142–152.)| false
• Search Google Scholar
• Export Citation

Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:754–766.

• PubMed
Palumbo A, Chanan-Khan A, Weisel K, Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:754–766.)| false
• Search Google Scholar
• Export Citation

Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015;373:1207–1219.

• PubMed
Lokhorst HM, Plesner T, Laubach JP, Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015;373:1207–1219.)| false
• Search Google Scholar
• Export Citation

Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016;387:1551–1560.

• PubMed
Lonial S, Weiss BM, Usmani SZ, Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016;387:1551–1560.)| false
• Search Google Scholar
• Export Citation

Mateos MV, Sonneveld P, Hungria V, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. Clin Lymphoma Myeloma Leuk 2020;20:509–518.

• PubMed
Mateos MV, Sonneveld P, Hungria V, Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. Clin Lymphoma Myeloma Leuk 2020;20:509–518.)| false
• Search Google Scholar
• Export Citation

Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol 2019;20:781–794.

• PubMed
Richardson PG, Oriol A, Beksac M, Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol 2019;20:781–794.)| false
• Search Google Scholar
• Export Citation

Dimopoulos M, Weisel K, Moreau P, et al. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia 2021;35:1722–1731.

• PubMed
Dimopoulos M, Weisel K, Moreau P, Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia 2021;35:1722–1731.)| false
• Search Google Scholar
• Export Citation

Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet 2020;396:1563–1573.

• PubMed
Grosicki S, Simonova M, Spicka I, Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet 2020;396:1563–1573.)| false
• Search Google Scholar
• Export Citation

Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 2018;379:1811–1822.

• PubMed
Dimopoulos MA, Dytfeld D, Grosicki S, Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 2018;379:1811–1822.)| false
• Search Google Scholar
• Export Citation

Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J Clin Oncol 2023;41:568–578.

• PubMed
Dimopoulos MA, Dytfeld D, Grosicki S, Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J Clin Oncol 2023;41:568–578.)| false
• Search Google Scholar
• Export Citation

Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016;17:27–38.

• PubMed
Dimopoulos MA, Moreau P, Palumbo A, Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016;17:27–38.)| false
• Search Google Scholar
• Export Citation

Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 2017;18:1327–1337.

• PubMed
Dimopoulos MA, Goldschmidt H, Niesvizky R, Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 2017;18:1327–1337.)| false
• Search Google Scholar
• Export Citation

Lonial S, Dimopoulos MA, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015;373:621–631.

• PubMed
Lonial S, Dimopoulos MA, Palumbo A, Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015;373:621–631.)| false
• Search Google Scholar
• Export Citation

Dimopoulos MA, Lonial S, White D, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol 2017;178:896–905.

• PubMed
Dimopoulos MA, Lonial S, White D, Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol 2017;178:896–905.)| false
• Search Google Scholar
• Export Citation

Dimopoulos MA, Lonial S, White D, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J 2020;10:91.

• PubMed
Dimopoulos MA, Lonial S, White D, Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J 2020;10:91.)| false
• Search Google Scholar
• Export Citation

Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol 2014;15:1503–1512.

• PubMed
Kumar SK, Berdeja JG, Niesvizky R, Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol 2014;15:1503–1512.)| false
• Search Google Scholar
• Export Citation

Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;374:1621–1634.

• PubMed
Moreau P, Masszi T, Grzasko N, Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;374:1621–1634.)| false
• Search Google Scholar
• Export Citation

Davies FE, Wu P, Jenner M, et al. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica 2007;92:1149–1150.

• PubMed
Davies FE, Wu P, Jenner M, The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica 2007;92:1149–1150.)| false
• Search Google Scholar
• Export Citation

Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007;138:330–337.

• PubMed
Kropff M, Bisping G, Schuck E, Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007;138:330–337.)| false
• Search Google Scholar
• Export Citation

Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009;27:5713–5719.

• PubMed
Richardson PG, Weller E, Jagannath S, Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009;27:5713–5719.)| false
• Search Google Scholar
• Export Citation

Richardson PG, Xie W, Jagannath S, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood 2014;123:1461–1469.

• PubMed
Richardson PG, Xie W, Jagannath S, A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood 2014;123:1461–1469.)| false
• Search Google Scholar
• Export Citation

Yong KL, Hinsley S, Auner HW, et al. Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK five). Haematologica 2021;106:2694–2706.

• PubMed
Yong KL, Hinsley S, Auner HW, Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK five). Haematologica 2021;106:2694–2706.)| false
• Search Google Scholar
• Export Citation

Puertas B, González-Calle V, Sureda A, et al. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients. Haematologica 2023;108:2753–2763.

• PubMed
Puertas B, González-Calle V, Sureda A, Randomized phase II study of weekly carfilzomib 70 mg/m² and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients. Haematologica 2023;108:2753–2763.)| false
• Search Google Scholar
• Export Citation

Yimer H, Melear J, Faber E, et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol 2019;185:492–502.

• PubMed
Yimer H, Melear J, Faber E, Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol 2019;185:492–502.)| false
• Search Google Scholar
• Export Citation

Jakubowiak A, Offidani M, Pégourie B, et al. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood 2016;127:2833–2840.

• PubMed
Jakubowiak A, Offidani M, Pégourie B, Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood 2016;127:2833–2840.)| false
• Search Google Scholar
• Export Citation

Kumar SK, Buadi FK, LaPlant B, et al. Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 2018;8:70.

• PubMed
Kumar SK, Buadi FK, LaPlant B, Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 2018;8:70.)| false
• Search Google Scholar
• Export Citation

Dimopoulos MA, Grosicki S, Jędrzejczak WW, et al. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Eur J Cancer 2019;106:89–98.

• PubMed
Dimopoulos MA, Grosicki S, Jędrzejczak WW, All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Eur J Cancer 2019;106:89–98.)| false
• Search Google Scholar
• Export Citation

Kumar SK, Grzasko N, Delimpasi S, et al. Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma. Br J Haematol 2019;184:536–546.

• PubMed
Kumar SK, Grzasko N, Delimpasi S, Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma. Br J Haematol 2019;184:536–546.)| false
• Search Google Scholar
• Export Citation

Morgan GJ, Schey SA, Wu P, et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007;137:268–269.

• PubMed
Morgan GJ, Schey SA, Wu P, Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007;137:268–269.)| false
• Search Google Scholar
• Export Citation

Baz RC, Martin TG 3rd, Lin HY, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood 2016;127:2561–2568.

• PubMed
Baz RC, Martin TG 3rd, Lin HY, Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood 2016;127:2561–2568.)| false
• Search Google Scholar
• Export Citation

Garderet L, Polge E, Gueye mS, et al. Pomalidomide, cyclophosphamide and dexamethasone for relapsed/refractory multiple myeloma: a retrospective single center experience. Blood 2015;126:1858.

• PubMed
Garderet L, Polge E, Gueye mS, Pomalidomide, cyclophosphamide and dexamethasone for relapsed/refractory multiple myeloma: a retrospective single center experience. Blood 2015;126:1858.)| false
• Search Google Scholar
• Export Citation

Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892–3901.

• PubMed
Orlowski RZ, Nagler A, Sonneveld P, Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892–3901.)| false
• Search Google Scholar
• Export Citation

Mikhael JR, Belch AR, Prince HM, et al. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol 2009;144:169–175.

• PubMed
Mikhael JR, Belch AR, Prince HM, High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol 2009;144:169–175.)| false
• Search Google Scholar
• Export Citation

Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165–172.

• PubMed
Jagannath S, Barlogie B, Berenson J, A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165–172.)| false
• Search Google Scholar
• Export Citation

Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006;91:929–934.

• PubMed
Jagannath S, Richardson PG, Barlogie B, Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006;91:929–934.)| false
• Search Google Scholar
• Export Citation

Dimopoulos MA, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–2132.

• PubMed
Dimopoulos MA, Spencer A, Attal M, Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–2132.)| false
• Search Google Scholar
• Export Citation

Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–2142.

• PubMed
Weber DM, Chen C, Niesvizky R, Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–2142.)| false
• Search Google Scholar
• Export Citation

Mikhael JR, Reeder CB, Libby EN, et al. Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. Br J Haematol 2015;169:219–227.

• PubMed
Mikhael JR, Reeder CB, Libby EN, Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. Br J Haematol 2015;169:219–227.)| false
• Search Google Scholar
• Export Citation

Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol 2018;19:953–964.

• PubMed
Moreau P, Mateos MV, Berenson JR, Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol 2018;19:953–964.)| false
• Search Google Scholar
• Export Citation

Gasparetto C, Schiller GJ, Tuchman SA, et al. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. Br J Cancer 2022;126:718–725.

• PubMed
Gasparetto C, Schiller GJ, Tuchman SA, Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. Br J Cancer 2022;126:718–725.)| false
• Search Google Scholar
• Export Citation

Schiller GJ, Tuchman SA, Callander N, et al. Once weekly selinexor, carfilzomib and dexamethasone (XKd) in triple class refractory multiple myeloma. Blood 2022;140(Suppl 1):10050–10053.

• PubMed
Schiller GJ, Tuchman SA, Callander N, Once weekly selinexor, carfilzomib and dexamethasone (XKd) in triple class refractory multiple myeloma. Blood 2022;140(Suppl 1):10050–10053.)| false
• Search Google Scholar
• Export Citation

Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood 2017;130:2401–2409.

• PubMed
Kumar S, Kaufman JL, Gasparetto C, Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood 2017;130:2401–2409.)| false
• Search Google Scholar
• Export Citation

Basali D, Chakraborty R, Rybicki L, et al. Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma. Br J Haematol 2020;189:1136–1140.

• PubMed
Basali D, Chakraborty R, Rybicki L, Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma. Br J Haematol 2020;189:1136–1140.)| false
• Search Google Scholar
• Export Citation

Kaufman JL, Gasparetto C, Schjesvold FH, et al. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. Am J Hematol 2021;96:418–427.

• PubMed
Kaufman JL, Gasparetto C, Schjesvold FH, Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. Am J Hematol 2021;96:418–427.)| false
• Search Google Scholar
• Export Citation

Bahlis NJ, Baz R, Harrison SJ, et al. Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol 2021;39:3602–3612.

• PubMed
Bahlis NJ, Baz R, Harrison SJ, Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol 2021;39:3602–3612.)| false
• Search Google Scholar
• Export Citation

Costa LJ, Stadtmauer EA, Morgan G, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood 2018;132(Suppl 1):303.

• PubMed
Costa LJ, Stadtmauer EA, Morgan G, Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood 2018;132(Suppl 1):303.)| false
• Search Google Scholar
• Export Citation

Abuelgasim KA, Alherz N, Alhejazi A, et al. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature. J Med Case Reports 2020;14:54.

• PubMed
Abuelgasim KA, Alherz N, Alhejazi A, Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature. J Med Case Reports 2020;14:54.)| false
• Search Google Scholar
• Export Citation

Görgün G, Calabrese E, Soydan E, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010;116:3227–3237.

• PubMed
Görgün G, Calabrese E, Soydan E, Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010;116:3227–3237.)| false
• Search Google Scholar
• Export Citation

Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:1055–1066.

• PubMed
Miguel JS, Weisel K, Moreau P, Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:1055–1066.)| false
• Search Google Scholar
• Export Citation

Dimopoulos MA, Palumbo A, Weisel K, et al. Safety and efficacy in the stratus (MM-010) trial, a single-arm phase 3b study evaluating pomalidomide + low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma. Blood 2014;124:80.

• PubMed
Dimopoulos MA, Palumbo A, Weisel K, Safety and efficacy in the stratus (MM-010) trial, a single-arm phase 3b study evaluating pomalidomide + low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma. Blood 2014;124:80.)| false
• Search Google Scholar
• Export Citation

Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood 2013;121:1968–1975.

• PubMed
Leleu X, Attal M, Arnulf B, Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood 2013;121:1968–1975.)| false
• Search Google Scholar
• Export Citation

Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011;118:2970–2975.

• PubMed
Lacy MQ, Allred JB, Gertz MA, Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011;118:2970–2975.)| false
• Search Google Scholar
• Export Citation

White D, Chen C, Baljevic M, et al. Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM). J Clin Oncol 2021;39(Suppl):Abstract 8018.

• PubMed
White D, Chen C, Baljevic M, Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM). J Clin Oncol 2021;39(Suppl):Abstract 8018.)| false
• Search Google Scholar
• Export Citation

Lazzarino M, Corso A, Barbarano L, et al. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant 2001;28:835–839.

• PubMed
Lazzarino M, Corso A, Barbarano L, DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant 2001;28:835–839.)| false
• Search Google Scholar
• Export Citation

Dadacaridou M, Papanicolaou X, Maltesas D, et al. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J BUON 2007;12:41–44.

• PubMed
Dadacaridou M, Papanicolaou X, Maltesas D, Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J BUON 2007;12:41–44.)| false
• Search Google Scholar
• Export Citation

Griffin PT, Ho VQ, Fulp W, et al. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma. Cancer 2015;121:3622–3630.

• PubMed
Griffin PT, Ho VQ, Fulp W, A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma. Cancer 2015;121:3622–3630.)| false
• Search Google Scholar
• Export Citation

Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003;21:2732–2739.

• PubMed
Lee CK, Barlogie B, Munshi N, DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003;21:2732–2739.)| false
• Search Google Scholar
• Export Citation

Srikanth M, Davies FE, Wu P, et al. Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. Eur J Haematol 2008;81:432–436.

• PubMed
Srikanth M, Davies FE, Wu P, Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. Eur J Haematol 2008;81:432–436.)| false
• Search Google Scholar
• Export Citation

Buda G, Orciuolo E, Galimberti S, et al. VDTPACE as salvage therapy for heavily pretreated MM patients. Blood 2013;122:5377.

• PubMed
Buda G, Orciuolo E, Galimberti S, VDTPACE as salvage therapy for heavily pretreated MM patients. Blood 2013;122:5377.)| false
• Search Google Scholar
• Export Citation

Andoh S, Togano T, Itoi S, et al. Efficacy and safety of VTD-PACE regimen in relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2017;17(Suppl):e57.

• PubMed
Andoh S, Togano T, Itoi S, Efficacy and safety of VTD-PACE regimen in relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2017;17(Suppl):e57.)| false
• Search Google Scholar
• Export Citation

Lakshman A, Singh PP, Rajkumar SV, et al. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. Am J Hematol 2018;93:179–186.

• PubMed
Lakshman A, Singh PP, Rajkumar SV, Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. Am J Hematol 2018;93:179–186.)| false
• Search Google Scholar
• Export Citation

Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 2023;29:2259–2267.

• PubMed
Lesokhin AM, Tomasson MH, Arnulf B, Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 2023;29:2259–2267.)| false
• Search Google Scholar
• Export Citation

Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 2022;387:2232–2244.

• PubMed
Chari A, Minnema MC, Berdeja JG, Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 2022;387:2232–2244.)| false
• Search Google Scholar
• Export Citation

Moreau P, Garfall AL, van de Donk NW, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022;387:495–505.

• PubMed
Moreau P, Garfall AL, van de Donk NW, Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022;387:495–505.)| false
• Search Google Scholar
• Export Citation

Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384:705–716.

• PubMed
Munshi NC, Anderson LD Jr, Shah N, Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384:705–716.)| false
• Search Google Scholar
• Export Citation

Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021;398:314–324.

• PubMed
Berdeja JG, Madduri D, Usmani SZ, Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021;398:314–324.)| false
• Search Google Scholar
• Export Citation

Martin T, Usmani SZ, Berdeja JG, et al. Updated results from CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. Blood 2021;138(Suppl 1):549.

• PubMed
Martin T, Usmani SZ, Berdeja JG, Updated results from CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. Blood 2021;138(Suppl 1):549.)| false
• Search Google Scholar
• Export Citation

Knop S, Straka C, Haen M, et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90:1287–1288.

• PubMed
Knop S, Straka C, Haen M, The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90:1287–1288.)| false
• Search Google Scholar
• Export Citation

Michael M, Bruns I, Bölke E, et al. Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res 2010;15:13–19.

• PubMed
Michael M, Bruns I, Bölke E, Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res 2010;15:13–19.)| false
• Search Google Scholar
• Export Citation

Lenhard RE Jr, Oken MM, Barnes JM, et al. High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma. Cancer 1984;53:1456–1460.

• PubMed
Lenhard RE Jr, Oken MM, Barnes JM, High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma. Cancer 1984;53:1456–1460.)| false
• Search Google Scholar
• Export Citation

Offidani M, Corvatta L, Maracci L, et al. Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J 2013;3:e162.

• PubMed
Offidani M, Corvatta L, Maracci L, Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J 2013;3:e162.)| false
• Search Google Scholar
• Export Citation

Gay F, Günther A, Offidani M, et al. Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: the EMN09 phase 1/2 study of the European Myeloma Network. Cancer 2021;127:3413–3421.

• PubMed
Gay F, Günther A, Offidani M, Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: the EMN09 phase 1/2 study of the European Myeloma Network. Cancer 2021;127:3413–3421.)| false
• Search Google Scholar
• Export Citation

Lentzsch S, O’Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 2012;119:4608–4613.

• PubMed
Lentzsch S, O’Sullivan A, Kennedy RC, Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 2012;119:4608–4613.)| false
• Search Google Scholar
• Export Citation

Rivell GL, Brunson CY, Milligan L, et al. Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents. Am J Hematol 2011;86:699–701.

• PubMed
Rivell GL, Brunson CY, Milligan L, Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents. Am J Hematol 2011;86:699–701.)| false
• Search Google Scholar
• Export Citation

Shank BR, Primeaux B, Yeung EK, et al. Hyperfractionated cyclophosphamide and dexamethasone alone or in combination with daratumumab and/or carfilzomib for the treatment of relapsed or refractory multiple myeloma: a single-center retrospective analysis. Clin Lymphoma Myeloma Leuk 2023;23:279–290.

• PubMed
Shank BR, Primeaux B, Yeung EK, Hyperfractionated cyclophosphamide and dexamethasone alone or in combination with daratumumab and/or carfilzomib for the treatment of relapsed or refractory multiple myeloma: a single-center retrospective analysis. Clin Lymphoma Myeloma Leuk 2023;23:279–290.)| false
• Search Google Scholar
• Export Citation

Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019;381:727–738.

• PubMed
Chari A, Vogl DT, Gavriatopoulou M, Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019;381:727–738.)| false
• Search Google Scholar
• Export Citation

Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020;21:207–221.

• PubMed
Lonial S, Lee HC, Badros A, Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020;21:207–221.)| false
• Search Google Scholar
• Export Citation

Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998;16:593–602.

• PubMed
Berenson JR, Lichtenstein A, Porter L, Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998;16:593–602.)| false
• Search Google Scholar
• Export Citation

Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488–493.

• PubMed
Berenson JR, Lichtenstein A, Porter L, Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488–493.)| false
• Search Google Scholar
• Export Citation

Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558–567.

• PubMed
Major P, Lortholary A, Hon J, Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558–567.)| false
• Search Google Scholar
• Export Citation

Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134:620–623.